NasdaqGS - Nasdaq Real Time Price USD

Kyverna Therapeutics, Inc. (KYTX)

2.3900

+0.3200

+(15.46%)

At close: 4:00:01 PM EDT

2.5000

+0.11

+(4.60%)

After hours: 5:24:23 PM EDT

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.

BioPharma Dive 4 days ago

AMGN

ALLO

KYTX
+15.46%
With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors

Key Insights Institutions' substantial holdings in Kyverna Therapeutics implies that they have significant influence...

Simply Wall St. 5 days ago

KYTX
+15.46%
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended March 31, 2025.

PR Newswire 7 days ago

KYTX
+15.46%
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the full year 2024.

PR Newswire last month

KYTX
+15.46%
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET.

PR Newswire 2 months ago

KYTX
+15.46%
3 US Penny Stocks With Market Caps Under $200M

The U.S. stock market has been experiencing fluctuations, with the S&P 500 recently reaching record highs while futures indicate a slightly lower open. Penny stocks, though an older term, still capture interest due to their potential for growth at accessible price points. These stocks often represent smaller or newer companies and can offer intriguing opportunities when backed by strong financials and fundamentals.

Simply Wall St. 2 months ago

PETS

KYTX
+15.46%

TSVT
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock

Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 3 months ago

KYTX
+15.46%
Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr. Gehchan brings 20 years of U.S. and international experience across multiple therapeutic areas, including immunology, as both a

PR Newswire 3 months ago

KYTX
+15.46%
Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 4 months ago

KYTX
+15.46%
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will present its 2025 strategic priorities and key milestones during a presentation that will be made by Chief Executive Officer, Warner Biddle, at the 43rd Annual J.P. Morgan Healthcare Conference today, Monday, January 13, 2025.

PR Newswire 4 months ago

KYTX
+15.46%
Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors

SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today the appointment of Abbas Kazimi and Mert Aktar to its Board of Directors. "We are honored to welcome Abbas and Mert to our Board of Directors," said Cameron Pye, Ph.D., CEO and Co-Founder of Unnatural Products. "Abbas has an exceptional history of advancing groundbreaking therapies and forging i

GlobeNewswire 4 months ago

KYTX
+15.46%
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced that the Company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. Warner Biddle, Chief Executive Officer of Kyverna, will present its 2025 strategic priorities and key milestones during a presentation on Monday, January 13, 2025, at 5:15 p.m. PST.

PR Newswire 4 months ago

KYTX
+15.46%
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations.

PR Newswire 5 months ago

KYTX
+15.46%
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop

Key Insights Institutions' substantial holdings in Kyverna Therapeutics implies that they have significant influence...

Simply Wall St. 5 months ago

KYTX
+15.46%
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announces today that it will present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase 1/2 studies and named patient treatments. Kyverna, alongside leading academic collaborators, will highlight all six patients treated with the target dose of 1×108 CD19 CAR T cells, four of whic

PR Newswire 6 months ago

KYTX
+15.46%
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2024.

PR Newswire 6 months ago

KYTX
+15.46%
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotechnology executive and cell therapy veteran Mert Aktar as an independent director to its Board of Directors. Mr. Aktar has over two decades of biopharmaceutical experience, melding more than a decade of technical leadership in cell and gene therapy with a proven track record

PR Newswire 6 months ago

KYTX
+15.46%
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy

We recently published a list of 7 Best Nano Cap Stocks To Invest In. In this article, we are going to take a look at where Kyverna Therapeutics, Inc. (NASDAQ:KYTX) stands against other best nano cap stocks to invest in. What Are the Small Cap Bulls Saying? In one of our recent articles about 8 Most […]

Insider Monkey 6 months ago

KYTX
+15.46%
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc

Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price of $4.89 per share, reflects a strategic move by the firm, emphasizing its interest in the biotechnology sector. Profile of JPMorgan Chase & Co. Founded in 1799, JPMorgan Chase & Co. has evolved into one of the world's leading financial institutions, with a presence in over 60 countries.

GuruFocus.com 7 months ago

KYTX
+15.46%

JPM
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the presentation of three posters outlining the design and methods of Kyverna's clinical trials evaluating KYV-101 in neuroinflammatory diseases at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, taking place September 1

PR Newswire 7 months ago

KYTX
+15.46%

Performance Overview

Return	KYTX	S&P 500 (^GSPC)
YTD	-36.10%	+1.00%
1-Year	-83.40%	+11.91%
3-Year	-92.07%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kyverna Therapeutics, Inc. (KYTX)

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

3 US Penny Stocks With Market Caps Under $200M

What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy

JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

Performance Overview